Richter Transformation clinical trials at UCSF

1 research study open to eligible people

Richter transformation happens when a slow-growing blood cancer turns into a fast-growing one. UCSF is conducting research to see if a new drug, NX-1607, is safe and works against advanced cancers. This study is the first to try NX-1607 in people.

Showing trials for

  • NX-1607 in Adults With Advanced Malignancies

    open to eligible people ages 18 years and up

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    San Francisco, California and other locations

Last updated: